Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Successful treatment with L-asparaginase-based regimen for primary pulmonary NK/T cell lymphoma: a case report and review of the literature.

Gui W, Yang B, Shen Q, Bai M, Wang J, Guan T, Zhao J, Wang J, Su L.

Clin Respir J. 2015 Oct;9(4):493-6. doi: 10.1111/crj.12156. Epub 2014 May 29. Review.

PMID:
24761980
2.

L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.

Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, ThiƩblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O.

Ann Oncol. 2009 Jan;20(1):110-6. doi: 10.1093/annonc/mdn542. Epub 2008 Aug 13. Review.

PMID:
18701429
3.

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9. doi: 10.1182/blood-2010-09-307454. Epub 2010 Dec 1.

4.

[A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].

Yuan F, Wei X, Yin Q, Li Y, Mi R, Ai H, Yang H, Li H, Ge S, Liu Y, Song Y.

Zhonghua Xue Ye Xue Za Zhi. 2014 Jul;35(7):614-8. doi: 10.3760/cma.j.issn.0253-2727.2014.07.010. Chinese.

PMID:
25052604
5.

Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.

Xiong X, Cai Z, Yang J, Shu X.

J Cancer Res Ther. 2015 Jul-Sep;11(3):665. doi: 10.4103/0973-1482.140750.

6.

Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.

Zang J, Li C, Luo SQ, Wang JH, Xu M, Zhao LN, Li WW, Yang H, Xiao F, Hitchcock YJ, Shi M.

Ann Hematol. 2015 Apr;94(4):583-91. doi: 10.1007/s00277-014-2244-4. Epub 2014 Nov 21.

PMID:
25409913
7.

Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L.

Cancer. 2012 Jul 1;118(13):3294-301. doi: 10.1002/cncr.26629. Epub 2011 Dec 2.

8.

Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.

Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J.

Hematol Oncol. 2006 Mar;24(1):28-32.

PMID:
16323259
9.
10.

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.

Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K.

Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.

11.

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.

Kim SJ, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS.

Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.

PMID:
24947798
12.

[Primary colonic extranasal NK/T-cell lymphoma: about a case].

Fares S, Lamchahab M, Aniba M, Lembarki G, Mousalli N, Regragui M, Karkouri M, Quessar A.

Pan Afr Med J. 2017 Mar 1;26:112. doi: 10.11604/pamj.2017.26.112.10304. eCollection 2017. French.

13.

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

PMID:
21990393
14.

Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.

Li L, Zhang C, Zhang L, Li X, Wu JJ, Sun ZC, Fu XR, Wang XH, Chang Y, Wang R, Qiu YJ, Zhang MZ.

Neoplasma. 2014;61(2):225-32. doi: 10.4149/neo_2014_029.

PMID:
24299319
15.

Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).

Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS.

Ann Hematol. 2015 Mar;94(3):437-44. doi: 10.1007/s00277-014-2228-4. Epub 2014 Oct 11.

PMID:
25300500
16.

[Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].

Wan WL, Wang J, Zhu MX, Zhang W, Ke XY.

Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Oct 18;48(5):841-845. Chinese.

17.

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.

Wang JH, Wang H, Wang YJ, Xia ZJ, Huang HQ, Jiang WQ, Lu Y.

Oncotarget. 2016 Jun 7;7(23):35412-22. doi: 10.18632/oncotarget.8643.

18.

Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.

Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, Sun Z, Zhang X, Li Z, Yan J, Chang Y, Lu L, Qin B, Li X, Wen J, Zhang M.

Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13.

PMID:
24923454
19.

L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.

Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J.

Ann Hematol. 2009 Jul;88(7):647-52. doi: 10.1007/s00277-008-0669-3. Epub 2008 Dec 24.

PMID:
19107482
20.

A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.

Ji J, Liu T, Xiang B, Liu W, He C, Chen X, Li J, Chang H, Dai Y, Dong T.

Leuk Lymphoma. 2014 Dec;55(12):2955-7. doi: 10.3109/10428194.2014.907894. Epub 2014 May 6. No abstract available.

PMID:
24679007

Supplemental Content

Support Center